Amneal Pharmaceuticals Subsidiary Kashiv Biosciences Gets FDA Approval Of Fylentra
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761084
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack production at high voltage R&D facility in Monrovia, California.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Amneal Pharmaceuticals’ Bevacizumab-Maly Granted FDA Approval
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process#:~:text=04/13/2022,Approval
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.
Amneal Pharmaceuticals’s Return On Capital Employed Insights
Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting in a loss of $20.46 million.
Amneal Pharmaceuticals Q4 EPS $0.18 Misses $0.20 Estimate, Sales $537.00M Miss $537.35M Estimate
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.20 by 10 percent. This is a 28.57 percent increase over earnings of $0.14 per share from